PCN101 Real-World Economic Outcomes of First-Line (1L) Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.193
https://www.valueinhealthjournal.com/article/S1098-3015(21)00410-1/fulltext
Title :
PCN101 Real-World Economic Outcomes of First-Line (1L) Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00410-1&doi=10.1016/j.jval.2021.04.193
First page :
Section Title :
Open access? :
No
Section Order :
10769